Prostate

Papers
(The H4-Index of Prostate is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
VOC‐based detection of prostate cancer using an electronic nose and ion mobility spectrometry: A novel urine‐based approach52
Prognostic value of circulating tumor cells in oligorecurrent hormone‐sensitive prostate cancer patients undergoing stereotactic body radiation therapy45
Non‐cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy40
34
The role of PSMA PET/CT to predict upgrading in patients undergoing radical prostatectomy for ISUP grade group 1 prostate cancer34
Rates of metastatic prostate cancer in newly diagnosed patients: Numbers needed to image according to risk level31
Impact of androgen receptor alterations on cell‐free DNA genomic profiling on survival outcomes in metastatic castration‐resistant prostate cancer27
Incidental Brain Metastases From Prostate Cancer Diagnosed With PSMA PET/CT and MRI: A Case Series and Literature Review26
Continuity of care in acute survivorship phase, and short and long‐term outcomes in prostate cancer patients25
Prostate cancer cells survive anti‐androgen and mitochondrial metabolic inhibitors by modulating glycolysis and mitochondrial metabolic activities24
24
Prognostic factors of overall and prostate‐specific antigen‐progression‐free survival in metastatic castration‐resistant prostate cancer patients treated with 177Lu‐PSMA‐617. A single‐cente24
24
The effect of tranexamic acid on perioperative blood loss in transurethral resection of the prostate: A double‐blind, randomized controlled trial23
Histopathologic Features and Transcriptomic Signatures Do Not Solve the Issue of Magnetic Resonance Imaging‐Invisible Prostate Cancers: A Matched‐Pair Analysis21
Comparison of circulating tumor DNA between African American and Caucasian patients with metastatic castrate‐resistant prostate cancer post‐abiraterone and/or enzalutamide20
Association of plasma NRP2 and VEGF‐C levels with prostate cancer disease severity20
A west African ancestry‐associated SNP on 8q24 predicts a positive biopsy in African American men with suspected prostate cancer following PSA screening20
3βHSD activity saturates at physiological substrate concentrations in intact cells20
Real‐world study: Impact of multidisciplinary management of apalutamide‐associated adverse events in prostate cancer19
Smoothened loss is a characteristic of neuroendocrine prostate cancer19
Genetic polymorphisms at 19q13.33 are associated with [−2]proPSA (p2PSA) levels and provide additional predictive value to prostate health index for prostate cancer19
A panel‐based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration‐resistant prostate cancer19
0.089943170547485